Opinion | The Pharmaceutical Industry Heads Into Elon Musk’s Wood Chipper
Who needs N.I.H. grants? A lot of red-state universities, for one.
Related Articles
Elon Musk and investors offering $97.4 billion for control of OpenAI, WSJ reports
According to the Wall Street Journal, Elon Musk and a group of investors are offering $97.4 billion to take control of OpenAI.
AI as Legal Persons: Past, Patterns, and Prospects
This paper examines the debate on AI legal personhood, emphasizing the role of path dependencies in shaping current trajectories and prospects. Three p
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
Single-cell and spatial multiomics analyses identify breakout lesions as a hotspot for tumor-immune interactions and diversification.
Milvue Secures Its Second FDA Clearance, Strengthening Its Leadership in Medical AI
Milvue obtains FDA clearance for TechCare Trauma, its AI-powered solution for musculoskeletal pathology detection and triage.
Elon Musk’s Business Empire Scores Benefits Under Trump Shake-Up
Government investigations into Mr. Musk’s companies are stalling from President Trump’s firings and Biden administration resignations.
Court Halt on Trump Cuts for Medical Research Is Extended Nationwide
The federal order temporarily halts the Trump administration’s plans to slash $4 billion in overhead costs for research at universities and medical centers into diseases…
Artificial intelligence using a latent diffusion model enables the generation of diverse and potent antimicrobial peptides
A pipeline using latent diffusion model generates antimicrobial peptides to combat antibiotic resistance.
Alzheimer’s scientist resigns after university finds ‘data integrity concerns’ in papers
University of Minnesota’s Sylvain Lesné has been at the heart of an image-doctoring scandal on key amyloid protein linked to dementia
Opinion | Trump Can’t Kill Green Energy
The 20-year move toward lower emissions won’t stop just because of the president.
